European Leukemia Trial Registry
Trial: Gilead GS-US-352-0101

More Details
Title Phase 3 Study evaluating Momelotinib vs. Ruxolitinib in subjects with in PMF, Post-PV-MF, Post-ET-MF
Scientific Title A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Short Title Gilead GS-US-352-0101
Trialgroup NN
Type of Trial randomized, double-blind
Disease Myeloproliferative disease(MPD) Myelofibrosis
Age >= 18 years
Status Active
Start of Recruitment 22.10.2013
Leader Döhner, Prof. Dr. med., Konstanze
Shortprotocol Shortprotocol
Remark Endpunkt: Milzresponse an Woche 24
created 03.09.2014 Johannes Kraus
changed 28.11.2014 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |